128 related articles for article (PubMed ID: 33277936)
21. Evaluating the thrombin generation profiles of four different rFVIII products in FVIII-deficient plasma using FIXa and FXIa activation.
Brophy DF; Martin EJ; Ninivaggi M; Mohammed BM; Barrett JC; Kuhn J; Nolte ME; Waters EK; Ezban M
Haemophilia; 2018 Sep; 24(5):815-822. PubMed ID: 30112856
[TBL] [Abstract][Full Text] [Related]
22. Flebogamma(®) DIF (intravenous immunoglobulin) purification process effectively eliminates procoagulant activities.
José M; Marzo N; Pons B; Herrerias A; López L; Faro M; López M; Jorquera JI
Biologicals; 2013 Nov; 41(6):393-9. PubMed ID: 24051302
[TBL] [Abstract][Full Text] [Related]
23. Activated factor XI and tissue factor in chronic obstructive pulmonary disease: links with inflammation and thrombin generation.
Jankowski M; Undas A; Kaczmarek P; Butenas S
Thromb Res; 2011 Mar; 127(3):242-6. PubMed ID: 21236471
[TBL] [Abstract][Full Text] [Related]
24. Factors associated with the presence of circulating active tissue factor and activated factor XI in stable angina patients.
Ząbczyk M; Butenas S; Plicner D; Fijorek K; Sadowski J; Undas A
Blood Coagul Fibrinolysis; 2012 Apr; 23(3):189-94. PubMed ID: 22343680
[TBL] [Abstract][Full Text] [Related]
25. Endothelial PAI-1 (Plasminogen Activator Inhibitor-1) Blocks the Intrinsic Pathway of Coagulation, Inducing the Clearance and Degradation of FXIa (Activated Factor XI).
Puy C; Ngo ATP; Pang J; Keshari RS; Hagen MW; Hinds MT; Gailani D; Gruber A; Lupu F; McCarty OJT
Arterioscler Thromb Vasc Biol; 2019 Jul; 39(7):1390-1401. PubMed ID: 31242030
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of factor XIa-alpha 1-antitrypsin in plasma, a contact phase-activated coagulation factor-inhibitor complex, in patients with coronary artery disease.
Murakami T; Komiyama Y; Masuda M; Karakawa M; Iwasaka T; Takahashi H
Arterioscler Thromb Vasc Biol; 1995 Aug; 15(8):1107-13. PubMed ID: 7627703
[TBL] [Abstract][Full Text] [Related]
27. The effect of corn trypsin inhibitor and inhibiting antibodies for FXIa and FXIIa on coagulation of plasma and whole blood.
Hansson KM; Nielsen S; Elg M; Deinum J
J Thromb Haemost; 2014 Oct; 12(10):1678-86. PubMed ID: 25142753
[TBL] [Abstract][Full Text] [Related]
28. Optimization of the thrombin generation test components to measure potency of factor VIII concentrates.
Jha NK; Shestopal SA; Gourley MJ; Woodle SA; Liang Y; Sarafanov AG; Weinstein M; Ovanesov MV
Haemophilia; 2016 Sep; 22(5):780-9. PubMed ID: 27038076
[TBL] [Abstract][Full Text] [Related]
29. Activation of the contact system in patients with a first acute myocardial infarction.
Konings J; Govers-Riemslag JW; Spronk HM; Waltenberger JL; ten Cate H
Thromb Res; 2013 Jul; 132(1):138-42. PubMed ID: 23746628
[TBL] [Abstract][Full Text] [Related]
30. Inactivation of factor XIa in human plasma assessed by measuring factor XIa-protease inhibitor complexes: major role for C1-inhibitor.
Wuillemin WA; Minnema M; Meijers JC; Roem D; Eerenberg AJ; Nuijens JH; ten Cate H; Hack CE
Blood; 1995 Mar; 85(6):1517-26. PubMed ID: 7534133
[TBL] [Abstract][Full Text] [Related]
31. Coagulation factor XI induces Ca
Liu W; Hashimoto T; Yamashita T; Hirano K
Am J Physiol Cell Physiol; 2019 Mar; 316(3):C377-C392. PubMed ID: 30566391
[TBL] [Abstract][Full Text] [Related]
32. The interaction of factor XIa with activated platelets but not endothelial cells promotes the activation of factor IX in the consolidation phase of blood coagulation.
Baird TR; Walsh PN
J Biol Chem; 2002 Oct; 277(41):38462-7. PubMed ID: 12167623
[TBL] [Abstract][Full Text] [Related]
33. Generation and characterization of aptamers targeting factor XIa.
Woodruff RS; Ivanov I; Verhamme IM; Sun MF; Gailani D; Sullenger BA
Thromb Res; 2017 Aug; 156():134-141. PubMed ID: 28644959
[TBL] [Abstract][Full Text] [Related]
34. Design and synthesis of a multivalent catch-and-release assay to measure circulating FXIa.
van der Beelen SHE; Agten SM; Suylen DPL; Wichapong K; Hrdinova J; Mees BME; Spronk HMH; Hackeng TM
Thromb Res; 2021 Apr; 200():16-22. PubMed ID: 33513452
[TBL] [Abstract][Full Text] [Related]
35. Clearance of human factor XIa-inhibitor complexes in rats.
Wuillemin WA; Bleeker WK; Agterberg J; Rigter G; ten Cate H; Hack CE
Br J Haematol; 1996 Jun; 93(4):950-4. PubMed ID: 8703832
[TBL] [Abstract][Full Text] [Related]
36. Structural Basis for Activity and Specificity of an Anticoagulant Anti-FXIa Monoclonal Antibody and a Reversal Agent.
Ely LK; Lolicato M; David T; Lowe K; Kim YC; Samuel D; Bessette P; Garcia JL; Mikita T; Minor DL; Coughlin SR
Structure; 2018 Feb; 26(2):187-198.e4. PubMed ID: 29336885
[TBL] [Abstract][Full Text] [Related]
37. Selection and characterization of a DNA aptamer inhibiting coagulation factor XIa.
Donkor DA; Bhakta V; Eltringham-Smith LJ; Stafford AR; Weitz JI; Sheffield WP
Sci Rep; 2017 May; 7(1):2102. PubMed ID: 28522812
[TBL] [Abstract][Full Text] [Related]
38. Factor XI and recurrent venous thrombosis: an observational cohort study.
Kyrle PA; Eischer L; Šinkovec H; Eichinger S
J Thromb Haemost; 2019 May; 17(5):782-786. PubMed ID: 30784172
[TBL] [Abstract][Full Text] [Related]
39. Combined thrombogenic effects of vessel injury, pregnancy and procoagulant immune globulin administration in mice.
Xu Y; Liang Y; Parunov L; Despres D; Eckhaus M; Scott D; Ovanesov M; Struble EB
Thromb J; 2020 Nov; 18(1):32. PubMed ID: 33292285
[TBL] [Abstract][Full Text] [Related]
40. Characterization of a heparin binding site on the heavy chain of factor XI.
Zhao M; Abdel-Razek T; Sun MF; Gailani D
J Biol Chem; 1998 Nov; 273(47):31153-9. PubMed ID: 9813019
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
